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In patients with heart failure, chronic kidney disease (CKD) is common and 
associated with a higher risk of renal events than in patients without CKD. We 
assessed the renal effects of angiotensin/neprilysin inhibition in patients with 
heart failure and preserved ejection fraction (HFpEF) enrolled in PARAGON-HF. 
 
Methods 
In this randomized, double-blind, event-driven trial, we assigned 4,822 patients 
with HFpEF to receive sacubitril/valsartan (n=2419) or valsartan (n=2403). Herein 
we present the results of the pre-specified renal composite outcome (time to first 
occurrence of either: ≥50% reduction in eGFR, end-stage renal disease, or death 
from renal causes), the individual components of this composite, and the 
influence of therapy on eGFR slope.  
 
Results 
At randomization, eGFR was 63±19 ml/min/1.73m2.  At study closure, the 
composite renal outcome occurred in 33 patients (1.4%) assigned to 
sacubitril/valsartan and 64 patients (2.7%) assigned to valsartan (hazard ratio 
[HR], 0.50; 95%CI, 0.33 to 0.77; P=0.001).  The treatment effect on the 
composite renal endpoint did not differ according to the baseline eGFR (<60 vs ≥ 
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60 ml/min/1.73 m2 (P-interaction=0.92). The decline in eGFR was less for 
sacubitril/valsartan compared with valsartan (-1.8 [95%CI, -2.0 to -1.6] vs. -2.4 
[95%CI, -2.6 to -2.2] ml/min/1.73m2/year).   
 
Conclusions 
In patients with HFpEF, sacubitril/valsartan reduced the risk of renal events, and 
slowed decline in eGFR, compared with valsartan. 
 
Trial Registration 




What Is New? 
• In this prespecified analysis of patients with heart failure with preserved 
ejection fraction enrolled in PARAGON-HF, sacubitril/valsartan reduced 
the occurrence of the renal composite outcome (≥50% reduction in eGFR, 
end-stage renal disease, or death from renal causes) compared with 
valsartan. 
• Sacubitril/valsartan attenuated the decline in estimated glomerular filtration 
rate over the course of the study, independent of changes in blood 
pressure, compared with valsartan. 
 
What Are the Clinical Implications? 
• Therapeutic benefits of sacubitril/valsartan with respect to renal outcomes 
are observed among patients with heart failure with preserved ejection 
fraction and appear to be similar across baseline kidney function. 
• Sacubitril/valsartan may represent an important therapeutic option to slow 
kidney function decline in patients with heart failure with preserved 




Chronic kidney disease (CKD) is a common comorbid condition in patients with 
heart failure, and is associated with a higher risk for adverse cardiovascular (CV) 
events, compared to heart failure patients without CKD.1–3 Heart failure with 
preserved ejection fraction (HFpEF) accounts for approximately half of heart 
failure cases, and includes features of diastolic dysfunction, vascular stiffness 
and abnormalities in systolic function.4,5 Inhibitors of the renin-angiotensin system 
(RAS) are known to reduce mortality in patients with heart failure with reduced 
ejection fraction (HFrEF),6–9 and to slow the progression of proteinuric CKD in 
patients with diabetes.10–12 However, in patients with HFpEF, RAS inhibition has 
not demonstrated conclusive benefit in reducing mortality or adverse renal 
outcomes.13–16  
 The addition of neprilysin inhibition to RAS blockade offers an alternative 
approach to target abnormal neurohormonal signaling in heart failure by 
augmenting the endogenous vasoactive peptide system, including the biologically 
active natriuretic peptides, while simultaneously blocking the renin-angiotensin 
system. In patients with heart failure and reduced ejection fraction (HFrEF) 
enrolled in the PARADIGM-HF trial, sacubitril/valsartan has been shown to 
reduce the risk of CV death and HF hospitalization,17 and to result in a slower 
rate of estimated glomerular filtration rate (eGFR) decline,18 compared with 
enalapril. Similar patterns of benefit in slowing eGFR decline were noted in a 
phase 2 trial of sacubitril/valsartan in HFpEF, compared with valsartan.19 
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The PARAGON-HF trial compared sacubitril/valsartan with valsartan in 
patients with HFpEF, and demonstrated a 13% reduction (rate ratio 0.87; 95%CI 
0.75 to 1.01) in total heart failure hospitalizations and CV death.20 Here, we 
report the results of the prespecified secondary renal outcome (composite of 
either a ≥50% reduction in eGFR relative to baseline, development of end-stage 
renal disease, or death from renal causes), the effect of study treatment on 
change in eGFR, and the effect of treatment on renal outcomes according to 





The sponsor of this trial is committed to sharing access to patient-level data and 
supporting clinical documents from eligible studies with qualified external 
researchers. These requests are reviewed and approved by an independent 
review panel based on scientific merit. All data provided is anonymized to respect 
the privacy of patients who have participated in the trial in line with applicable 
laws and regulations. The trial data availability is according to the criteria and 
process described.21 
 
Trial design and oversight 
The design and methods of the PARAGON-HF trial have been described 
previously.20,22	 Local ethics committees approved the trial and all patients 
provided written, informed consent.  The executive committee designed and 
oversaw the conduct of the trial and data analysis in collaboration with the 
sponsor, Novartis.  A full copy of the trial protocol is available with this article.  
The trial was reviewed by an independent data and safety monitoring committee. 
Data were collected, managed, and analyzed by the sponsor according to a 
predefined statistical analysis plan.  An independent academic statistician 
replicated the primary analyses. The first author wrote the first draft of the 
present manuscript.  All authors submitted revisions and made the collective 




Briefly, the PARAGON-HF study population included patients aged ≥50 years, 
left ventricular ejection fraction ≥45% by echocardiography with features of 
structural heart disease defined by left ventricular hypertrophy and/or left atrial 
enlargement, on maintenance diuretic therapy and with elevated plasma B-type 
natriuretic peptide (BNP) or N-terminal pro-B-type natriuretic peptide (NTproBNP) 
concentrations.  Notable exclusion criteria included: symptomatic hypotension (or 
a systolic blood pressure <110 mm Hg at screening or <100 mm Hg at random 
treatment assignment); an eGFR of <30 ml/min/1.73 m2 at screening or <25 
ml/min/1.73 m2 at randomization, or a decrease >35% in eGFR between 
screening and randomization; and hyperkalemia (serum potassium >5.2 mmol/l 
at screening or >5.4 mmol/l at random treatment assignment).  
 
Definition of Primary and Secondary Outcomes  
The primary outcome of the PARAGON-HF trial was a composite of CV death 
and total (first and recurrent) heart failure hospitalizations.  The composite renal 
outcome was a prespecified key secondary outcome, defined as either: 1) ≥50% 
decline in eGFR relative to baseline; 2) development of end-stage renal disease; 




Post Hoc Assessments of Renal Outcomes 
We conducted post-hoc analyses to examine for the effect of sacubitril/valsartan 
(versus valsartan) on the individual components of the renal composite endpoint.  
In addition, we examined for a differential effect of sacubitril/valsartan on the 
renal outcome, according to the baseline eGFR (eGFR at randomization, 
modeled as a continuous variable).  A prespecified exploratory outcome was to 
examine if sacubitril/valsartan resulted in a slower rate of decline in eGFR, 
compared with valsartan.  For these analyses, the eGFR was calculated using 
the Chronic Kidney Disease Epidemiology Collaboration equation, with creatinine 
traceable to isotope dilution mass spectrometry, using data from randomization, 
at 4, 16, 32, and 48 weeks, and every 24 weeks thereafter until week 192.  
 
Renal Safety and Laboratory Assessments 
We conducted safety analyses to examine for a differential effect of 
sacubitril/valsartan for the incidence of at least one adverse event, at least one 
serious adverse event, study drug discontinuation for adverse and serious 
adverse events, hyperkalemia, elevations in serum creatinine, and symptomatic 
hypotension, according to the baseline eGFR (<60 versus ≥60 ml/min/1.73 m2).   
 
Statistical Analyses 
We report data as mean (+/-SD) when normally distributed, as median (25th-75th 
percentile) when non-normally distributed, and as frequencies and percentages 
for categorical variables. We used the Student t-test, Wilcoxon Rank Sum, or chi-
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square tests to determine differences between baseline variables for patients 
according to the baseline (eGFR <60 versus ≥60 ml/min/1.73 m2, respectively), 
according to data distribution.     
We used an intention-to-treat approach to perform analyses in patients 
who had received at least one dose of study drug. For the renal endpoints we 
used Cox proportional hazard models to estimate hazard ratios (HRs) with 95% 
CIs, stratified according to geographic region. We tested for interactions between 
the treatment effect of sacubitril/valsartan and baseline eGFR, age, sex, and 
ejection fraction on the renal outcomes.  Data from patients who did not have an 
event were censored on the last day they were known to be free of the outcome.  
We assessed for changes in eGFR over time with repeated measures 
mixed effect models, using available data from randomization, at 4, 16, 32, and 
48 weeks, and every 24 weeks thereafter, until week 192.  We adjusted for 
treatment assignment, trial visit, and the interaction between treatment 
assignment and visit.  Intercepts and slopes over time were allowed to vary 
randomly between patients by inclusion of patient and time as random effects. As 
sacubitril/valsartan resulted in a lower mean blood pressure compared with 
valsartan, in exploratory models, we adjusted for time-updated measurements of 
systolic blood pressure. 
All analyses were performed at the nominal alpha level of 0.05 without 
correction for multiple hypothesis testing. No formal power calculations were 
performed a priori for renal secondary or exploratory outcomes. Statistical 
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analyses were performed using STATA (version 14.0, Stata Corp., College 






A total of 4822 patients were randomized, with 4796 included in the efficacy 
analysis (26 patients were excluded as they were enrolled at a site that was 
closed for violations of Good Clinical Practice; Figure 1).  At baseline, the mean 
eGFR was 63±19 ml/min/1.73 m2 and 47% of patients had an eGFR < 60 
ml/min/1.73 m2.  The patients were categorized according to the eGFR at 
baseline (<60 versus ≥60 ml/min/1.73m2) and had similar characteristics 
according to treatment assignment within these sub-groups (Table 1). Overall, at 
baseline, patients with eGFR < 60 ml/min/1.73 m2 (mean 47± 8 ml/min/1.73 m2) 
were more likely to be older, female, have a history of diabetes, atrial fibrillation 
or prior stroke, to be taking a diuretic, and have marginally higher ejection 
fraction and NTproBNP; they were less likely to be taking an ACEi or ARB, and 
had lower systolic blood pressure (Supplementary Table 2). The mean eGFR 
was 77± 14 ml/min/1.73 m2 in those with baseline eGFR ≥ 60 ml/min/1.73 m2. 
 
Prespecified Renal Outcomes 
The composite renal outcome occurred in 33 of the 2407 patients (1.4%) in the 
sabubitril/valsartan group and 64 of the 2389 patients (2.7%) in the valsartan 
group, with a risk reduction of 50% (HR 0.50, 95%CI 0.33-0.77; P=0.001; Fig. 2).  
The 4-year risk of experiencing the renal composite outcome was 2.1% in the 
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sacubitril/valsartan group and 4.1% in the valsartan group, corresponding to a 
number needed to treat of 51 (28, 220) over this time period.   
The treatment effect from an on-treatment analysis were similar to the 
intention-to-treat approach (HR 0.45; 95%CI 0.28 to 0.74).  The treatment effect 
on the composite renal endpoint did not differ according to the baseline eGFR 
(<60 vs ≥ 60 ml/min/1.73 m2; P-interaction=0.92; Table 2). Furthermore, there 
was no evidence for effect modification according to age (P-interaction=0.41), 
sex (P-interaction=0.90), or ejection fraction (P-interaction=0.31).   
The overall result from the renal composite outcome was driven by the 
individual component of ≥50% reduction in eGFR from baseline, which occurred 
in 27 of the 2407 patients (1.1%) in the sacubitril/valsartan group and 60 of the 
2389 patients (2.5%) of the valsartan group (HR 0.44, 95%CI 0.28-0.69).  The 
development of ESRD occurred in 7 of 2407 patients (0.3%) in the 
sacubitril/valsartan group and in 12 of 2377 patients (0.5%) in the valsartan 
group (HR 0.58, 95%CI 0.23-1.47). There were 2 deaths from renal disease, with 
one occurring in the sacubitril/valsartan group and one in the valsartan group.  
The treatment effects on the individual components of the renal composite 
outcome did not differ according to the baseline eGFR (Table 2).   
 
Renal Function over Time 
From randomization through the end of study, the mean decline in eGFR was -
2.0 (95%CI -2.2 to -1.9) ml/min/1.73 m2 per year for the sacubitril/valsartan 
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group, compared with -2.7 (95%CI -2.8 to -2.5) ml/min/1.73 m2 per year for the 
valsartan group, with an adjusted mean difference of 0.6 (95%CI 0.4 to 0.9; 
P<0.001) ml/min/1.73 m2 per year (Fig. 3). Treatment effect estimates were 
similar after additional adjustment for changes in systolic blood pressure during 
the study (adjusted mean difference 0.6 (95%CI 0.3 to 0.8; P<0.001) ml/min/1.73 
m2 per year.   
 
  
Safety and Adverse Events 
Overall, adverse events requiring study drug discontinuation and serious adverse 
events, and permanent discontinuation due to renal impairment were more 
common among those with baseline eGFR < 60 ml/min/1.73 m2 (versus eGFR ≥ 
60 ml/min/1.73 m2).  Patients with baseline eGFR < 60 ml/min/1.73 m2 assigned 
to the sacubitril/valsartan group had more hypotensive events, fewer episodes of 
elevated serum creatinine above 2 mg/dL, and no difference in the frequency of 
hyperkalemic events.  Patients with baseline eGFR ≥ 60 ml/min/1.73 m2 assigned 
to the sacubitril/valsartan group had fewer episodes of serum creatinine ≥ 2 mg/dl 
or hyperkalemia ≥6 mmol/L, compared with the valsartan group (Supplementary 




Among patients with HFpEF in the PARAGON-HF trial, sacubitril/valsartan 
resulted in lower rates of the renal composite outcome than valsartan.  This result 
was driven mainly by a lower incidence of ≥50% decline in eGFR relative to 
baseline and was consistent across sub-groups of baseline eGFR (< 60 and ≥ 60 
ml/min/1.73m2). Patients in the sacubitril/valsartan group also had a lower overall 
rate of decline in eGFR, compared with those in the valsartan group.  
 There have been suggestions of renal benefit with combined angiotensin 
and neprilysin inhibition in prior studies of patients with heart failure.  For 
example, in the OVERTURE trial there were fewer adverse events of renal 
impairment with omapatrilat (versus enalapril) in patients with NYHA class II-IV 
heart failure or LVEF≤30%.23 In the PARADIGM-HF trial, while a significant 
decrease in the prespecified renal composite endpoint (end-stage renal disease, 
or decrease in eGFR of ≥50%, or a decrease of more than 30 ml/min/1.73 m2 
from randomization to less than 60 ml/min/1.73 m2) was not observed, a post hoc 
analysis examining the effect of sacubitril/valsartan on the more conventional 
composite of end-stage renal disease or ≥50% decline in eGFR did show a 
decreased risk (HR 0.63; 95% CI 0.42 – 0.95), while the rate of decline in eGFR 
was also lower.18 Overall, these results suggest beneficial renal effects for 
combined angiotensin/neprilysin inhibition in patients with heart failure across the 
spectrum of ejection fraction.  
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The renal benefits we observed in PARAGON-HF and PARADIGM-HF 
were not observed in the HARP-III trial, a relatively small trial which compared 
sacubitril/valsartan with irbesartan in 414 patients with CKD (eGFR 20-60 
ml/min/1.73 m2) of various etiologies.  HARP-III observed no significant 
difference between groups in the primary outcome of measured eGFR at 12 
months.24 Of note, compared with participants of PARAGON-HF, those in HARP-
III tended to be younger, predominantly male, had higher blood pressure, more 
advanced CKD and higher levels of proteinuria, and a very low prevalence of 
self-reported heart failure and diuretic use. These differences in patient 
characteristics, the smaller sample size, the much shorter duration of follow up, 
and the inclusion of a heterogenous group of CKD etiologies in HARP-III, may 
explain the discrepant results in renal outcomes between the two studies.   
Sacubitril/valsartan lowered systolic blood pressure to a greater extent 
than valsartan in PARAGON-HF and was associated with a higher frequency of 
hypotensive events.  Despite these differences, the occurrence of adverse renal 
events was lower with sacubitril/valsartan.  Indeed, in additional analyses that 
adjusted for changes in systolic blood pressure, there still appeared to be benefit 
for sacubitril/valsartan in terms of a lower rate of decline in eGFR during the 
course of the study.  These findings suggest that the beneficial renal effects are 
independent of blood pressure lowering. 
 The activation of several neurohormonal pathways in heart failure, 
including the renin-angiotensin system and the counter-regulatory natriuretic 
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peptide system, have important consequences for renal hemodynamics.  
Micropuncture studies in rodent models of heart failure have reported higher 
glomerular capillary pressures compared with controls, which are lowered with 
angiotensin converting enzyme (ACE) blockade.25  Furthermore, omapatrilat (an 
inhibitor of both ACE and neprilysin) appeared to result in further reduction of 
intra-glomerular pressure, compared with enalapril.26  However, the clinical 
relevance of these observations is uncertain, as several post-hoc analyses of 
randomized trials in heart failure have not found evidence for longer-term 
preservation of renal function (and potentially even accelerated decline) with the 
use of RAS inhibitors, versus placebo. 27–31 Similarly, trials of beta-blocker 
therapy in heart failure have also failed to result in renal benefits,32 suggesting 
that optimization of cardiac function alone is not enough to attenuate renal 
function decline in heart failure.  While it could be debated if the renal benefit we 
observed is reflective of less ARB effect with sacubitril/valsartan than single-
agent valsartan, pharmacokinetic studies suggest bioequivalence in ARB dosing 
with the respective sacubitril/valsartan formulation.33  Furthermore, similar renal 
benefits were observed in PARADIGM-HF, compared with enalapril, suggesting 
the renal benefits are not limited to differences in the hemodynamic effects of 
ARBs.  Thus, our present findings suggest that simultaneous inhibition of the 
renin-angiotensin and neprilysin systems has opposing effects on the 
determinants of glomerular function.  Additionally, it is likely that several non-
hemodynamic pathways are also affected by combined angiotensin/neprilysin 
	 19	
inhibition, with some evidence suggesting an anti-inflammatory role for neprilysin 
inhibition (beyond that of RAS inhibitors alone) in terms of reducing biomarkers of 
renal fibrosis and inflammation.34,35  
It is important to view these results in the context of recent therapeutic 
advances with sodium-glucose cotransporter 2 (SGLT2) inhibitors which have 
been shown to have long-term renal benefit  in patients with T2DM, compared 
with placebo.36–40  While the mean difference in eGFR decline in our analyses 
was 0.7 ml/min/1.73m2/year, compared with 1.5 ml/min/1.73m2/year in 
CREDENCE, there were major differences in the study design, including the 
specific recruitment of individuals with CKD (without requirement for HFpEF) and 
use of placebo-control in CREDENCE,36 as well as different mechanisms of 
action and blood pressure lowering effects.  In contrast to the initial decline in 
eGFR observed over the first few months of SGLT2 inhibitor therapy compared 
with placebo, we noted some minor fluctuations in eGFR until the 32-week 
measurement, perhaps reflective of titration of study medication dosing.  Despite 
this, we still found significant attenuation of eGFR decline for sacubitril/valsartan 
over the course of follow-up, in both intention-to-treat and on-treatment analyses. 
Longer term renal outcome data with SGLT2 inhibitors in the specific setting of 
heart failure is limited to date.41  
 There are some limitations to the present analyses.  Although the 
composite renal outcome was a key prespecified secondary outcome of 
PARAGON-HF, the trial was not primarily powered for analyses of the individual 
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renal components, nor for assessment of differences in eGFR decline.   Urine 
albumin/creatinine ratio was not measured during the course of this study, 
limiting our ability to compare with PARADIGM-HF where, although CV benefits 
were maintained, modest increases in microalbuminuria were noted with 
sacubitril/valsartan, compared with enalapril.  PARAGON-HF excluded patients 
with more advanced kidney disease (eGFR <30 ml/min/1.73 m2) and had a 
modest proportion of non-Caucasians, thereby limiting generalizability of our 
findings to such populations.  
In summary, in patients with HFpEF enrolled in the PARAGON-HF trial, 
treatment with sacubitril/valsartan resulted in fewer adverse renal events and 
slower decline in eGFR, despite a higher frequency of hypotensive events. 
Notably, these renal benefits appear to extend across the spectrum of baseline 
renal function, providing an important therapeutic option to slow renal function 
decline in patients with heart failure.  
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Table 1.  Characteristics of the Patients at Baseline, According to the Estimated Glomerular Filtration Rate 
(eGFR) and Randomized Treatment Assignment.a 
Characteristic Patients with eGFR <60 ml/min/1.73m2 Patients with eGFR ≥60 ml/min/1.73m2 








Age, yrs 75.2 ± 7.6 74.9 ± 7.6 70.4 ± 8.8 70.7 ± 8.5 
Female, no. (%) 645     (54.8) 675     (58.0) 593     (49.0) 566     (45.5) 
Race, no. (%)     
     Asian 141     (12.0) 132     (11.3) 168     (13.9) 165     (13.3) 
     Black 23      (2.0) 23      (2.0) 27      (2.2) 29      (2.3) 
     Other 40      (3.4) 42      (3.6) 45      (3.7) 53      (4.3) 
     White  973     (82.7) 967     (83.1) 971     (80.2) 996     (80.1) 
Geographic Region, 
no. (%)     
     North America 175 (14.9) 176 (15.1) 96 (7.9) 112 (9.0) 
     Latin America 87 (7.4) 88 (7.6) 92 (7.6) 103 (8.3) 
     Western Europe 370 (31.4) 387 (33.2) 320 (26.4) 312 (25.1) 
     Central Europe 360 (30.6) 349 (30.0) 499 (41.2) 507 (40.8) 
     Asia-Pacific or 
other 185 (15.7) 164 (14.1) 204 (16.9) 209 (16.8) 
Systolic blood 
pressure, mmHg 130.0 ± 15.8 129.2 ± 16.1 131.2 ± 14.9 131.7 ± 14.9 
Heart rate, beats/min 70.0 ± 12.3 70.7 ± 12.5 70.6 ± 12.1 70.5 ± 12.1 
Body-mass indexc 30.3 ± 5.0 30.4 ± 4.9 30.3 ± 5.2 30.0 ± 4.9 
	 22	
Serum creatinine, 




47 ± 8 47 ± 8 77 ± 15 77 ± 14 
Clinical features of 
heart failure     
     Ischemic Cause, 
no. (%) 403     (34.2) 416     (35.8) 421     (34.8) 483     (38.9) 
     Left ventricular 




1025  [522 – 
1854] 
 
1060  [556  - 1809] 
 
780   [400  - 1464] 
 
764   [414  - 1407] 
 
NYHA Classification, 
no. (%)     
     I 34      (2.9) 33      (2.8) 30      (2.5) 40      (3.2) 
     II 892     (75.8) 884     (76.0) 947     (78.2) 982     (79.1) 
     III 246     (20.9) 244     (21.0) 228     (18.8) 214     (17.2) 
     IV 5       (0.4) 2       (0.2) 6       (0.5) 6       (0.5) 
Medical History, no. 
(%)     
     Hypertension 1128    (95.8) 1118    (96.0) 1151    (95.0) 1186    (95.4) 
     Diabetes 537     (45.6) 512     (44.0) 478     (39.5) 534     (43.0) 
     Atrial Fibrillation or 413     (35.3) 405     (34.9) 364     (30.1) 370     (29.8) 
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flutter 
     Stroke 138     (11.8) 148     (12.7) 104     (8.6) 118     (9.5) 
     Hospitalization for 
heart failure 592     (50.3) 549     (47.2%) 579     (47.8) 586     (47.1) 
     Myocardial 
infarction 258     (21.9) 265     (22.8%) 264     (21.8) 296     (23.8) 
Treatment, no. (%)     
     Diuretic at 
randomization 1142    (97.0) 1121    (96.3) 1148    (94.8) 1173    (94.4) 
     ACE inhibitor or 
ARB at screening 1002    (85.1) 983     (84.5) 1063    (87.8) 1091    (87.8) 
     Mineralocorticoid-
receptor antagonist at 
randomization 
317     (26.9) 285     (24.5) 330     (27.3) 307     (24.7) 
     Beta-blocker at 
randomization 918     (78.0) 926     (79.6) 980     (80.9) 996     (80.1) 
 
a Plus-minus values are mean +/- SD.  There were no significant differences between the study groups except with 
respect to ischemia as a primary cause of heart failure in patients with eGFR ≥60 ml/min/1.73 m2 (P=0.04).   
b The GFR at baseline was estimated according to the four-variable Modification of Diet in Renal Disease formula.  Data 
on eGFR at baseline was not available for one patient in the Valsartan group. 
c The body-mass index is the weight in kilograms divided by the square of the height in meters. 
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d This characteristic was measured at the randomization visit instead of the screening visit. 




Table 2.  Renal Outcomes 
 
Outcome Valsartan  
 
Sacubitril/Valsartan  Hazard Ratio 
(95% CI) 
Overall  (n=2389) (n=2407)  
Renal Composite, no. (%) 64 (2.7) 33 (1.4) 0.50 (0.33-0.77) 
     >50% decline in eGFR 60 (2.5) 27 (1.1) 0.44 (0.28-0.69) 
     End-stage renal disease 12 (0.5) 7 (0.3) 0.58 (0.23-1.47) 
     Death from renal causes 1 (0.04) 1 (0.04) – 
    
Patients with baseline 
eGFR < 60 ml/min/1.73m2  
(n=1177) (n=1164)  
Renal Composite, no. (%) 32 (2.7) 16 (1.4) 0.50 (0.28-0.92) 
     >50% decline in eGFR 28 (2.4) 11 (1.0) 0.39 (0.20-0.79) 
     End-stage renal disease 12 (1.0) 6 (0.5) 0.51 (0.19-1.35) 
     Death from renal causes 1 (0.04) 1 (0.04) – 
    
Patients with baseline 
eGFR ≥60 ml/min/1.73m2  
(n=1211) (n=1243)  
Renal Composite, no. (%) 32 (2.6) 17 (1.4) 0.51 (0.29-0.93) 
     >50% decline in eGFR 32 (2.6) 16 (1.3) 0.48 (0.27-0.88) 
     End-stage renal disease 0 (0.0) 1 (0.1) – 




Figure 1. Consort Flow Diagram 
 
 
Entered valsartan run-in (N = 5,746) 
(median duration 15 days, IQR 12 – 22 days) 
Patients screened (N = 10,359) 
Discontinuation = 541 
Primary reasons of run-in failure 
Adverse event n = 340 
Subject/guardian decision n = 98 
Protocol deviation n = 62 
Other n = 41 
Entered sacubitril/valsartan run-in (N = 5,205†) 
(median duration 19 days, IQR 15 – 23 days) 
Discontinuation = 384 
Primary reasons of run-in failure 
Adverse event n = 262 
Subject/guardian decision n = 37 
Protocol deviation n = 49 
Other n = 36 
Randomized (N = 4,822*) 
Allocated to sacubitril/valsartan 
N = 2,407 
x Final vital status known = 2,402 
x Final vital status unknown = 5 
Allocated to valsartan 
N = 2,389 
x Final vital status known = 2,385 
x Final vital status unknown = 4 
 
Allocated to sacubitril/valsartan 
N = 2,419 
Allocated to valsartan 
N = 2,403 
Patients from one site prematurely 
closed on 27-Jun-2017 due to major 
GCP violations 
n = 12 
Patients from one site prematurely 
closed on 27-Jun-2017 due to major 
GCP violations 
n = 14 
IQR = interquartile range; GCP = Good Clinical Practice; †One patient completed screening and entered the sacubitril/valsartan run-in without 
entering the valsartan run-in; *One patient completed the valsartan run-in and was randomized without entering the sacubitril/valsartan run-in 
 
Screen failures = 4,612 
Primary reasons of screen failure 
Not meeting entry criteria n = 4,308 
Subject/guardian decision n = 259 




Figure 2. Kaplan-Meier Analysis of Renal Outcomes 
Shown are estimates of the probability of a first occurrence of a prespecified 
renal composite outcome of either a ≥50% reduction in eGFR relative to baseline, 
attainment of end-stage renal disease, or death due to renal causes among 
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Figure 3. Change in renal function over time 
Shown are the adjusted means for the estimated glomerular filtration rate (eGFR) 
over a period of 192 weeks among patients who received at least one dose of 
either sacubitril/valsartan or valsartan.  The I bars indicate 95% confidence 
intervals.  The eGFR was calculated according to the creatinine formula 
developed by the Chronic Kidney Disease Epidemiology Collaboration study.  
This panel is based on a mixed-model, repeated measures analysis in patients 
who received at least one dose of study drug and had a baseline and post-
baseline measurement.  The number of measurements available at each 




-2.0 (95%CI -2.2 to -1.9) ml/min/1.73m2/year
































Change in eGFR over 192 weeks
S/V: 2,407  2,311   2,241   2,192        2,109      2,017         1,916         1,437          865         431
Val: 2,388  2,282   2,219   2,158        2,063      1,973         1,902         1,418          871         458
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Supplementary Table 1.  Prespecified Renal Endpoint Definitions 
Endpoint Criteria 
End-stage renal disease One of the following: 
a) Initiation of dialysis (e.g., hemodialysis, 
peritoneal dialysis, or continuous veno-venous 
hemodialysis), continuing for ≥ 30 days without 
known recovery of renal function, Sites were 
queried to provide evidence of continuation of 
dialysis for over 90 days.   
b) Initiation of dialysis with death before 30 days 
(excludes dialysis events associated with acute 
kidney injury with death before 30 days)   
c) A drop in eGFR from baseline (randomization, 
i.e. Visit 199/201) to a value <15 mL/min/1.73m2 
on two consecutive central laboratory 
measurements separated by ≥ 30 days. This event 
was identified programmatically by the sponsor   




Sustained reduction in estimated GFR (eGFR) by 50% 
from baseline (Randomization, Visit 199/201) as 
determined by 2 consecutive post-baseline central 
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laboratory measurements separated by > 30 days.  
This event was identified programmatically by the 
sponsor. 
Death from Renal 
Causes 
 
Death occurring from complications of renal failure (e.g. 
hyperkalemia, uremia, acidosis) after a patient refuses or 
a physician withholds renal replacement therapy (i.e. 
initiation of chronic dialysis or renal transplantation) or in 
cases where dialysis is unavailable.  
Such events were adjudicated as renal death only when 






Supplementary Table 2.  Characteristics of the Patients at Baseline 
According to the Estimated Glomerular Filtration Rate (eGFR).a 
Characteristic Patients with eGFR 
<60 ml/min/1.73m2 
(n=2341) 
Patients with eGFR ≥60 
ml/min/1.73m2 
(n=2454) 
Age, yrs 75.0 ± 7.6 70.6 ± 8.6 
Female, no. (%) 1320 (56.4) 1159 (47.2) 
Race, no. (%)   
     Asian 273 (11.7) 333 (13.6) 
     Black 46 (2.0) 56 (2.3) 
     Other 82 (3.5) 98 (4.0) 
     White  1940 (82.9) 1967 (80.2) 
Geographic Region, no. 
(%)   
     North America 351 (15.0) 208 (8.5) 
     Latin America 175 (7.5) 195 (8.0) 
     Western Europe 757 (32.3) 632 (25.8) 
     Central Europe 709 (30.3) 1006 (41.0) 
     Asia-Pacific or other 349 (14.9) 413 (16.8) 
Systolic blood pressure, 
mmHg 129.6 ± 16.0 131.5 ± 14.9 
Heart rate, beats/min 70.3 ± 12.4 70.5 ± 12.1 
Body-mass indexc 30.3 ± 4.9 30.1 ± 5.1 
Serum creatinine, mg/dL 




47 ± 8 77 ± 14 
Clinical features of heart 
failure   
     Ischemic Cause, no. 
(%) 819 (35.0) 904 (36.8) 
     Left ventricular 
ejection fraction, % 58.0 ± 7.8 57.1 ± 8.0 
Median NT-proBNP (25th-
75th percentile), pg/mL 
1040  [541 – 1820] 
 
770  [409  - 1438] 
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NYHA Classification, no. 
(%)   
     I 67 (2.9) 70  (2.9) 
     II 1776 (75.9) 1929 (78.6) 
     III 490 (20.9) 442 (18.0) 
     IV 7 (0.3) 12 (0.5) 
Medical History, no. (%)   
     Hypertension 2246 (95.9) 2337 (95.2) 
     Diabetes 1049 (44.8) 1012 (41.2) 
     Atrial Fibrillation or 
flutter 818 (35.1) 734 (30.0) 
     Stroke 286 (12.3) 222 (9.1) 
     Hospitalization for 
hearth failure 1141 (48.7) 1165 (47.5%) 
     Myocardial infarction 523 (22.3) 560 (22.8%) 
Treatment, no. (%)   
     Diuretic at 
randomization 2263 (96.7) 2321 (94.6) 
     ACE inhibitor or ARB 
at screening 1985 (84.8) 2154 (87.8) 
     Mineralocorticoid-
receptor antagonist at 
randomization 
602 (25.7) 637 (26.0) 
     Beta-blocker at 




1164 (49.7) 1243 (50.7) 
 
a Plus-minus values are mean +/- SD.  There were significant differences 
between the study groups with respect to age, sex, region, systolic blood 
pressure, creatinine, eGFR, ejection fraction, NTproBNP, diabetes mellitus, atrial 
fibrillation, stroke, diuretics, and ACEi/ARB use.   
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b The GFR at baseline was estimated according to the four-variable Modification 
of Diet in Renal Disease formula.  Data on eGFR at baseline was not available 
for one patient in the Valsartan group. 
c The body-mass index is the weight in kilograms divided by the square of the 
height in meters. 
d This characteristic was measured at the randomization visit instead of the 
screening visit. 
NYHA, New York Heart Association; BMI, Body Mass Index; ACE, Angiotensin 
Converting Enzyme; ARB, Angiotensin Receptor Blocker 
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Supplementary Table 3.  Key Adverse Events a 
 
Characteristic Patients with eGFR <60 
ml/min/1.73m2 
Patients with eGFR ≥60 
ml/min/1.73m2 
















n, no. (%) 










n, no. (%) 




n due to renal 
impairment, 
no. (%) 
68 (5.8) 57 (4.9) 22 (1.8) 13 (1.0) 
     
Hypotension 
with SBP <100 
mm Hg, no. 
(%) 
125 (10.6) 219 (18.8) 132 (10.9) 161 (13.0) 
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(%) 
     ≥2.0 mg/dl 274 (23.3) 231 (19.8) 54 (4.5) 30 (2.4) 
     ≥2.5 mg/dl 96 (8.2) 86 (7.4) 13 (1.1) 11 (0.9) 
     ≥3.0 mg/dl 34 (2.9) 32 (2.7) 6 (0.5) 6 (0.5) 
     
Hyperkalemia     
     >5.5 
mmol/L 212 (18.0) 183 (15.7) 149 (12.3) 133 (10.7) 
     >6 mmol/L 55 (4.7) 50 (4.3) 46 (3.8) 25 (2.0) 
 
a Shown are the results of prespecified safety events at any time after 
randomization for patients who received at least one dose of study drug (includes 
events that occurred during treatment or within 7 days of last receipt of study 
drug). In those with eGFR < 60 ml/min/1.73 m2 there were more hypotension 
events in the sacubitril/valsartan group (P<0.001), fewer events of serum 
creatinine ≥2 mg/dl (P=0.04), fewer adverse events requiring study drug 
discontinuation (P=0.04) and fewer serious adverse events requiring study drug 
discontinuation (P=0.04). In those with eGFR ≥ 60 ml/min/1.73 m2 there were 
significantly fewer events of serum creatinine ≥ 2 mg/dl (P=0.005) and 
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